{'fraction_non_alphanumeric': 0.018367346938775512, 'fraction_numerical': 0.00816326530612245, 'mean_word_length': 4.7015503875969, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A New Class of Pure Estrogen Alpha Receptor Antagonists; Design, Synthesis and in-vitro Screening



 In view of the estrogenic receptor inhibitory properties of coumarin
nucleus, long chain nature of fatty acid and anti-breast cancer activity of fatty acids, it was proposed
to attach long chain fatty acids at 3rd,4th and 7th position of coumarin nucleus and evaluate for their
anti-breast cancer activity through suitable in-vitro methods.



 The present study focuses a library of fatty acid coumarin conjugates as ligands to the
ligand-binding domain of the human estrogen receptor α (PDB ID 2IOG) and their binding affinities
using GLIDE module of Schrodinger after ascertaining their drug-likeness with QIKPROP. The
compounds LNAC 8, SAC 1 and OAC 5 are the best hits based on their docking scores as well as
the Prime MM-GBSA free energy of binding. Based on the in-silico results and synthetic feasibility
the compounds SAC 1 PAC 1 and OAC 1 are synthesized, characterized and investigated for their
time interval growth inhibitory effect on MCF-7 which is an ER positive breast cancer cell lines.



 SAC 1, showed better in vitro growth inhibitory effect in sub micromolar range as
compared to Tamoxifen, a standard estrogen receptor modulator.



 Conclusively, in silico molecular docking studies have been very useful in predicting
the pharmacokinetic profiles and the binding affinities of new hits before a detailed preclinical and
clinical evaluation.
